Vantage Consulting Group’s NovoCure NVCR Stock Holding History

Vantage Consulting Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10	Closed	-$2K	–	1069
2020 Q4	$2K	Buy	+10	New	+$1.37K	﹤0.01%	1664

Other funds holding NVCR

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vantage Consulting Group's NVCR Position: Q1 2021 in Review

Vantage Consulting Group sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 10 shares — an estimated $2K sold.

Vantage Consulting Group first reported a position in NVCR in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

Vantage Consulting Group reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 10 NovoCure shares in Q1 2021, an estimated $2K.
Vantage Consulting Group first reported a position in NovoCure in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's NovoCure position peaked at $2K in Q4 2020.
327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.